

Clas Malmestrm

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8366939/clas-malmestrom-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45
papers

2,083
citations

24
h-index

45
g-index

47
ext. papers

2,492
ext. citations

5.5
avg, IF

4.49
L-index

#	Paper	IF	Citations
45	Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. <i>Annals of Neurology</i> , 2011 , 69, 83-9	9.4	236
44	Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. <i>Neurology</i> , 2017 , 89, 2230-2237	6.5	205
43	Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy. <i>Neurology</i> , 2016 , 87, 2074-2081	6.5	187
42	Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016 , 79, 950-8	9.4	143
41	Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. <i>Journal of Neurology</i> , 2011 , 258, 882-8	5.5	96
40	Simvastatin as add-on therapy to interferon β 1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. <i>Lancet Neurology</i> , 2011 , 10, 691-701	24.1	92
39	Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. <i>Journal of Neurochemistry</i> , 2017 , 141, 296-304	6	87
38	Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 43-50	5	81
37	Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 2438-41	5.9	79
36	MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS). <i>BMC Immunology</i> , 2013 , 14, 32	3.7	65
35	Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013 , 128, e33-6	3.8	65
34	Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 62-71	5	64
33	Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 765-74	5	58
32	Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1587-1595	5	53
31	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 448-54	5.4	52
30	Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. <i>Journal of Neuroimmunology</i> , 2008 , 196, 159-65	3.5	49
29	IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles. <i>Journal of Neuroimmunology</i> , 2006 , 175, 176-82	3.5	47

28	YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2016 , 292, 52-7	3.5	43
27	CSF levels of YKL-40 are increased in MS and reduces with immunosuppressive treatment. <i>Journal of Neuroimmunology</i> , 2014 , 269, 87-9	3.5	43
26	An observational study of alemtuzumab following fingolimod for multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e320	9.1	41
25	Inflammation-related plasma and CSF biomarkers for multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12952-12960	11.5	39
24	Cerebrospinal fluid biomarkers of amyloid metabolism in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 543-52	5	37
23	Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. <i>European Journal of Neurology</i> , 2016 , 23, 796-806	6	35
22	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 264, 100-5	3.5	26
21	Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers. <i>PLoS ONE</i> , 2018 , 13, e0194828	3.7	21
20	Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2015 , 358, 201-6	3.2	19
19	Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. <i>Journal of Neuroimmunology</i> , 2017 , 306, 25-30	3.5	16
18	Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials. <i>Journal of Alzheimers Disease</i> , 2012 , 32, 273-6	4.3	16
17	Serum levels of LIGHT in MS. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 871-6	5	14
16	High Interferon- γ Uniquely in V β T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2017 , 8, 260	8.4	11
15	First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. <i>Journal of Neurology</i> , 2014 , 261, 2016-8	5.5	10
14	MS risk genes are transcriptionally regulated in CSF leukocytes at relapse. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 403-10	5	8
13	Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS. <i>Journal of Neurochemistry</i> , 2018 , 146, 322-332	6	7
12	Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis. <i>Neuroepidemiology</i> , 2015 , 45, 83-9	5.4	7
11	Neuronal antibodies in adult patients with new-onset seizures: A prospective study. <i>Brain and Behavior</i> , 2019 , 9, e01442	3.4	4

10	Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord lesion. <i>Neuroscience Letters</i> , 2010 , 483, 197-200	3.3	4
9	Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular Identifiers. <i>Clinical Chemistry</i> , 2020 , 66, 1228-1237	5.5	4
8	CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6,	9.1	4
7	Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 189-194	5.5	4
6	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. <i>Acta Neurologica Scandinavica</i> , 2019 , 139, 422-427	3.8	3
5	Intrathecal immunoreactivity in people with or without previous infectious mononucleosis. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 161-168	3.8	2
4	Cerebrospinal fluid CD4 /CD8 ratio in diagnosing neurosarcoidosis. <i>Acta Neurologica Scandinavica</i> , 2020 , 142, 480-485	3.8	2
3	A Sensitive Method for Detecting Peptide-specific CD4 T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis. <i>Frontiers in Immunology</i> , 2017 , 8, 1370	8.4	1
2	Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis. <i>Scientific Reports</i> , 2019 , 9, 17309	4.9	1
1	Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of life. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 52, 102977	4	